Despite the lack of deep value, there is something else: Akero Therapeutics Inc (AKRO) Stock
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
A Tale from the Dusty Corner: Akero Therapeutics Inc (AKRO) Stock
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
Akero Therapeutics Inc (AKRO) Stock is poised for a successful quarter
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
Why Akero Therapeutics Inc (NASDAQ:AKRO) Stock Increased 7.92 percent in recent Trade?
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
Akero Therapeutics Inc (AKRO) Stock is poised for a successful quarter
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
Why Akero Therapeutics Inc (NASDAQ:AKRO) Stock Slipped -3.22% in Last Month?
BofA Securities raised the price target for the Akero Therapeutics Inc (NASDAQ:AKRO) stock to “a Neutral”. The rating was released on April 22, 2024, according to finviz. The research report from UBS has initiated the stock to Buy, with a price target set at $83. The stock was upgraded by Morgan Stanley, who disclosed in […]
